NeoPhotonics Corporation (NYSE:NPTN) represented a move of 5.42 percent or $-0.39 per share and closed its previous day trading session at $5.84. 557368 Shares were traded in the last trading session with an Average Volume of 850.61 Million Shares. The stock currently has a Market Capitalization of 248.26 Million.
NeoPhotonics Corporation is engaged in the design and manufacture of photonic integrated circuit, or PIC, based modules and subsystems for bandwidth-intensive, high-speed communications networks. Products offered by the Company includes high-speed products that enable data transmission at 10Gbps, 40Gbps and 100Gbps, agility products such as ROADMs that dynamically allocate bandwidth to adjust for volatile traffic patterns, and access products that provide high-bandwidth connections to more devices and people over fixed and wireless networks.
The stock traded between $ 4.56 and $12.44 over 1-Year time period showing its price to sales ratio of 0.76. NeoPhotonics Corporation (NYSE:NPTN) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a INCREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-9.13 and 200-Day Simple Moving Average of $-15. Its Price to Free Cash Flow is 0 and Price to Book of 1.26.
Analyst’s recommended the stock as 2.3 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, NeoPhotonics Corporation (NYSE:NPTN) reported its Actual EPS of $-0.25/share. The analysts offering Earnings Estimates for the company were believing that NeoPhotonics Corporation could bring EPS of $-0.31/share. The difference between Actual EPS and Estimated EPS was 0.06 Percent. Thus showing an Earnings Surprise of 19.4 Percent.
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)
In the last trading session, Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) added its value by 4.04% closing at the price of $14.15. The stock currently has market capitalization of 397.05 Million, with average volume of 464.44 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) is showing beta of 0.65. This particular value of beta suggests that Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has historically moved 65% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) is at $-3.73.
The stock currently has RSI of 40.19. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company’s lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States.
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) topped its 52-week high price of $29.00 on 08/31/17 and 52-Week Low Price of $11.85 on 02/09/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 7.58% and monthly volatility of 4.26% respectively.